Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 20:01 | 2026-06-03 | OCUL | OCULAR THERAPEUTIX, INC | Waheed Nadia | Officer | SELL | $8.27 | 14,828 | $122,628 | 300,079 |
| 2026-06-05 17:46 | 2026-06-04 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | BUY | $9.31 | 50,000 | $465,295 | 936,000 |
| 2026-06-05 00:35 | 2026-06-03 | GNLX | GENELUX Corp | Smalling Ralph | Officer | SELL | $2.93 | 192 | $563 | 67,611 |
| 2026-06-05 00:00 | 2026-06-02 | JANX | Janux Therapeutics, Inc. | Doyle Janeen Noel | Officer | SELL | $14.03 | 4,059 | $56,944 | 75,941 |
| 2026-06-04 22:08 | 2026-06-04 | SMMT | Summit Therapeutics Inc. | DUGGAN ROBERT W | Director, Officer, 10% owner | BUY | $14.60 | 100,000 | $1,460,000 | 25,824,474 |
| 2026-06-04 21:45 | 2026-06-04 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Director, Officer, 10% owner | BUY | $14.60 | 100,000 | $1,460,000 | 25,824,474 |
| 2026-06-04 21:30 | 2026-06-04 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $547.07 | 8,300 | $4,540,643 | 45,172 |
| 2026-06-04 21:00 | 2026-06-04 | ALKS | Alkermes plc. | Gaffin David Joseph | Officer | SELL | $43.05 | 2,034 | $87,564 | 229,524 |
| 2026-06-04 20:40 | 2026-06-04 | SMMT | Summit Therapeutics Inc. | Soni Manmeet Singh | Director, Officer | BUY | $14.45 | 50,000 | $722,250 | 3,123,603 |
| 2026-06-04 20:49 | 2026-06-02 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $70.60 | 20,000 | $1,412,000 | 3,985 |
| 2026-06-04 20:30 | 2026-06-03 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $547.61 | 9,500 | $5,202,271 | 40,513 |
| 2026-06-04 20:00 | 2026-06-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew | Officer | OPT+S | $32.87 | 16,195 | $532,330 | 9,989 |
| 2026-06-03 20:30 | 2026-06-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $98.69 | 11,430 | $1,128,080 | 85,533 |
| 2026-06-03 20:06 | 2026-06-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer | SELL | $439.91 | 828 | $364,245 | 19,959 |
| 2026-06-03 20:31 | 2026-06-01 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $60.87 | 276 | $16,800 | 146,743 |
| 2026-06-03 20:10 | 2026-06-01 | ONC | BeOne Medicines Ltd. | Yi Qingqing | Director | SELL | $279.13 | 235 | $65,596 | 0 |
| 2026-06-03 20:30 | 2026-06-01 | LQDA | Liquidia Corp | KIRSCH ARTHUR S | Director | SELL | $57.71 | 30,000 | $1,731,300 | 0 |
| 2026-06-03 20:25 | 2026-06-01 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | PYOTT DAVID E I | Director | OPT+S | $299.18 | 3,830 | $1,145,853 | 1,582 |
| 2026-06-04 01:30 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $71.06 | 7,500 | $532,937 | 97,994 |
| 2026-06-04 01:31 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $70.43 | 15,000 | $1,056,486 | 597,540 |
| 2026-06-04 01:32 | 2026-06-03 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer | OPT+S | $75.00 | 8,333 | $624,975 | 0 |
| 2026-06-04 00:02 | 2026-06-01 | EVMN | Evommune, Inc. | Pena Luis C. | Director, Officer | SELL | $22.74 | 16,787 | $381,736 | 637,896 |
| 2026-06-04 00:02 | 2026-06-01 | EVMN | Evommune, Inc. | Patel Jeegar Pravinkumar | Officer | OPT+S | $22.74 | 16,687 | $379,462 | 46,403 |
| 2026-06-04 00:03 | 2026-06-02 | EVMN | Evommune, Inc. | Cohen David E | Director | SELL | $20.33 | 6,056 | $123,094 | 17,609 |
| 2026-06-03 23:20 | 2026-06-01 | CORT | CORCEPT THERAPEUTICS INC | Mokari Atabak | Officer | OPT+S | $70.00 | 40,000 | $2,800,004 | 15,257 |
| 2026-06-03 23:20 | 2026-06-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $70.21 | 25,000 | $1,755,183 | 8,977 |
| 2026-06-03 23:11 | 2026-06-01 | SEPN | Septerna, Inc. | Shaikhly Samira | Officer | OPT+S | $28.93 | 5,935 | $171,682 | 793 |
| 2026-06-03 22:37 | 2026-06-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | OPT+S | $22.87 | 27,000 | $617,571 | 115,743 |
| 2026-06-03 22:42 | 2026-06-01 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.46 | 139,803 | $63,624 | 482,776 |
| 2026-06-03 22:44 | 2026-06-01 | NATR | NATURES SUNSHINE PRODUCTS INC | Norman Daniel C | Officer | SELL | $20.64 | 9,713 | $200,476 | 47,276 |
| 2026-06-03 21:36 | 2026-06-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Officer | BUY | $7.50 | 13,500 | $101,219 | 75,300 |
| 2026-06-03 21:33 | 2026-06-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $30.58 | 1,795 | $54,891 | 34,826 |
| 2026-06-03 21:34 | 2026-06-01 | IONS | IONIS PHARMACEUTICALS INC | BERTHELSEN SPENCER R | Director | OPT+S | $75.67 | 8,000 | $605,360 | 156,013 |
| 2026-06-03 21:09 | 2026-06-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $235.12 | 6,000 | $1,410,720 | 372,682 |
| 2026-06-03 20:34 | 2026-06-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $538.39 | 9,500 | $5,114,742 | 40,513 |
| 2026-06-03 16:41 | 2026-06-02 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | BUY | $9.43 | 50,000 | $471,300 | 886,000 |
| 2026-06-02 20:25 | 2026-06-02 | ASND | Ascendis Pharma A/S | SMITH SCOTT THOMAS | Officer | BUY | $219.00 | 100 | $21,900 | 4,367 |
| 2026-06-02 20:30 | 2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | Officer | SELL | $18.99 | 1,177 | $22,351 | 139,252 |
| 2026-06-02 20:30 | 2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Director, Officer | SELL | $18.99 | 6,847 | $130,025 | 484,843 |
| 2026-06-02 20:05 | 2026-06-01 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $69.74 | 12,837 | $895,252 | 2,565,489 |
| 2026-06-03 01:54 | 2026-05-29 | AUPH | Aurinia Pharmaceuticals Inc. | TANG KEVIN | Director, Officer, 10% owner | BUY | $15.29 | 814,606 | $12,455,244 | 13,044,106 |
| 2026-06-03 00:35 | 2026-06-01 | GNLX | GENELUX Corp | Thomas John | Director | SELL | $2.98 | 10,000 | $29,801 | 472,784 |
| 2026-06-03 00:34 | 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $4.72 | 652 | $3,075 | 181,509 |
| 2026-06-02 23:50 | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $100.00 | 3,977 | $397,700 | 0 |
| 2026-06-02 23:50 | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | OPT+S | $95.84 | 30,000 | $2,875,104 | 194,309 |
| 2026-06-02 23:14 | 2026-06-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $16.60 | 8,148 | $135,253 | 13,579 |
| 2026-06-02 22:56 | 2026-05-29 | PAHC | PHIBRO ANIMAL HEALTH CORP | CORCORAN E THOMAS | Director | BUY | $31.77 | 10,000 | $317,700 | 41,459 |
| 2026-06-02 23:00 | 2026-05-29 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Director | SELL | $229.20 | 17,537 | $4,019,470 | 29,603 |
| 2026-06-02 23:00 | 2026-06-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Randhawa Simrat | Officer | OPT+S | $90.62 | 26,530 | $2,404,077 | 4,000 |
| 2026-06-02 22:46 | 2026-06-01 | NBP | NovaBridge Biosciences | Xu Cong Claire | Officer | OPT+S | $3.94 | 3,494 | $13,766 | 290,154 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.